

JOURNAL OF HEPATOLOGY

The Home of Liver Research

VOLUME 77, ISSUE 6, PAGES 1475–1734

FROM THE EDITOR'S DESK

From the Editor's Desk...

P. Burra, F. Tacke, V. Ratziu, S. Zeuzem, B. Sangro and P. Angeli 1475

EDITORIALS

Hepatic progenitor cells, senescence and IL-6 as the main players in combined hepatocellular-cholangiocarcinoma development

M. Arechederra and M.G. Fernández-Barrena 1479

RESEARCH ARTICLES

NAFLD and Alcohol-Related Liver Diseases

Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD

B.K. Kim, N. Tamaki, K. Imajo, M. Yoneda, N. Sutter, J. Jung, T. Lin, X.M. Tu, J. Bergstrom, K. Nguyen, L. Nguyen, T. Le, E. Madamba, L. Richards, M.A. Valasek, C. Behling, C.B. Sirlin, A. Nakajima and R. Loomba 1482

MRG15 aggravates non-alcoholic steatohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM

C. Tian, X. Min, Y. Zhao, Y. Wang, X. Wu, S. Liu, W. Dou, T. Zhou, Y. Liu, R. Luo, Z. Li, K.O. Lui, Y. Li, B. Zhou and Q. Ding 1491

Mitochondrial respiration is decreased in visceral but not subcutaneous adipose tissue in obese individuals with fatty liver disease

K. Paffli, S. Kahl, L. Mastrototaro, K. Strassburger, D. Pesta, C. Herder, J. Pützer, B. Dewidar, M. Hendlinger, C. Granata, N. Saatmann, A. Yavas, S. Gancheva, G. Heilmann, I. Esposito, M. Schlensak and M. Roden 1504

Viral Hepatitis

Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B

D. Ji, Y. Chen, J. Bi, Q. Shang, H. Liu, J.-B. Wang, L. Tan, J. Wang, Y. Chen, Q. Li, Q. Long, L. Song, L. Jiang, G. Xiao, Z. Yu, L. Chen, X. Wang, D. Chen, Z. Li, Z. Dong and Y. Yang 1515

Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension

E. Degasperis, M.P. Anolli, S.C. Uceda Renteria, D. Sambarino, M. Borghi, R. Perbellini, C. Scholtes, F. Facchetti, A. Loglio, S. Monico, M. Fraquelli, A. Costantino, F. Ceriotti, F. Zoulim and P. Lampertico 1525

DILI, Autoimmune, Cholestatic and Genetic Diseases

Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis

A.-L. Müller, C. Casar, M. Preti, D. Krzikalla, C. Gottwick, P. Averhoff, P. Rosenstiel, M. Gelderblom, M. Altfeld, A.W. Lohse, S. Steinmann, M. Sebode, J. Krause, D. Schwinge, C. Schramm, A. Carambia and J. Herkel 1532

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

C. Corpechot, F. Carrat, F. Gaouar, F. Chau, G. Hirschfield, A. Gulamhusein, A.J. Montano-Loza, E. Lytvyak, C. Schramm, A. Pares, I. Olivas, J.E. Eaton, K.T. Osman, G. Dalekos, N. Gatselis, F. Nevens, N. Cazzagon, A. Zago, F.P. Russo, N. Abbas, P. Trivedi, D. Thorburn, F. Saffiotti, L. Barkai, D. Roccarina, V. Calvaruso, A. Fichera, A. Delamarre, E. Medina-Morales, A. Bonder, V. Patwardhan, C. Rigamonti, M. Carbone, P. Invernizzi, L. Cristofori, A. van der Meer, R. de Veer, E. Zigmond, E. Yehezkel, A.E. Kremer, A. Deibel, J. Dumortier, T. Bruns, K. Große, G.-P. Pageaux, A. Wetten, J. Dyson, D. Jones, O. Chazouillères, B. Hansen and V. de Lédinghen on behalf of the Global & ERN Rare-Liver PBC Study Groups 1545

Cirrhosis and Liver Failure

Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis

T.H. Tranah, M.-P. Ballester, J.A. Carbonell-Asins, J. Ampuero, G. Alexandrino, A. Caracostea, Y. Sánchez-Torrijos, K.L. Thomsen, A.J.C. Kerbert, M. Capilla-Lozano, M. Romero-Gómez, D. Escudero-García, C. Montoliu, R. Jalan and D.L. Shawcross 1554

Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis

Q. Wang, H. Zhao, Y. Deng, H. Zheng, H. Xiang, Y. Nan, J. Hu, Q. Meng, X. Xu, J. Fang, J. Xu, X. Wang, H. You, C.Q. Pan, W. Xie and J. Jia 1564

Non-invasive tests for clinically significant portal hypertension after HCV cure

G. Semmler, S. Lens, E.L. Meyer, A. Baiges, E. Alvarado-Tapias, E. Llop, L. Tellez, P. Schwabl, E. Mauro, L. Escudé, C. Diez, L. Ibañez-Samaniego, Á. Puente, J.I. Fortea, M. Abadía, A. Zanetto, A. Conthe, H. Hernandez-Évole, I.S. Luzko Scheid, J. Jia, H. Yoshiji, S.M. Francque, E.A. Tsochatzis, F.P. Russo, G. Crespo, X. Fornis, R. Bañares, C. Villanueva, V. Hernández-Gea, T. Reiberger, J. Bosch, J.C. García Pagán M. Mandorfer and A study by the Baveno Cooperation: an EASL consortium 1573

Hepatic and Biliary Cancer

Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma

J. Calderaro, L. Di Tommaso, P. Maillé, A. Beaufrère, C.T. Nguyen, L. Heij, V. Gnemmi, R.P. Graham, F. Charlotte, S. Chartier, D. Wendum, M. Vij, D. Allende, A. Diaz, C. Fuster, B. Rivière, A. Herrero, J. Augustin, K. Evert, D.F. Calvisi, W.Q. Leow, H.H.W. Leung, J. Bednarsch, E. Boleslawski, M. Rela, A.W.-H. Chan, A. Forner, M. Reig, A. Pujals, L. Favre, M. Allaire, O. Scatton, A. Uguen, E. Trépo, L.O. Sanchez, D. Chatelain, M. Rimmelink, C. Boulagnon-Rombi, C. Bazille, N. Sturm, B. Menahem, E. Frouin, D. Tougeron, C. Tournigand, E. Kempf, H. Kim, M. Ningarahari, S. Michalak-Provost, J.N. Kather, A.S.H. Gouw, P. Gopal, R. Brustia, E. Vibert, K. Schulze, D.F. Rütther, S.A. Weidemann, R. Rhaïem, J.-C. Nault, A. Laurent, G. Amaddeo, H. Regnault, E. de Martin, C. Sempoux, P. Navale, J. Shinde, K. Bacchuwar, M. Westerhoff, R.C.-L. Lo, M. Sebbagh, C. Guettier, M. Lequoy, M. Komuta, M. Ziol, V. Paradis, J. Shen and S. Caruso 1586

Global burden of primary liver cancer in 2020 and predictions to 2040

H. Runggay, M. Arnold, J. Ferlay, O. Lesi, C.J. Cabasag, J. Vignat, M. Laversanne, K.A. McGlynn and I. Soerjomataram 1598

Liver Transplantation

Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicenter analysis of the US, the UK, and Canada

T. Ivanics, D. Wallace, M.P.A.W. Claasen, M.S. Patel, R. Brahmabhatt, C. Shwaartz, A. Prachalias, P. Srinivasan, W. Jassem, N. Heaton, M.S. Cattral, N. Selzner, A. Ghanekar, G. Morgenshtern, N. Mehta, A.B. Massie, J. van der Meulen, D.L. Segev and G. Sapisochin 1607

Experimental and Translational Hepatology

Hepatectomy-induced apoptotic extracellular vesicles stimulate neutrophils to secrete regenerative growth factors

V. Brandel, V. Schimek, S. Göber, T. Hammond, L. Brunthaler, W.C. Schrottmaier, M. Mussbacher, M. Sachet, Y.Y. Liang, S. Reipert, G. Ortmayr, D. Pereyra, J. Santol, M. Rainer, N. Walterskirchen, C. Ramos, V. Gerakopoulos, C. Rainer, A. Spittler, T. Weiss, R. Kain, B. Messner, T. Gruenberger, A. Assinger, R. Oehler and P. Starlinger 1619

Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling

N. Rosenberg, M. Van Haele, T. Lanton, N. Brashi, Z. Bromberg, H. Adler, H. Giladi, A. Peled, D.S. Goldenberg, J.H. Axelrod, A. Simerzin, C. Chai, M. Paldor, A. Markezana, D. Yaish, Z. Shemulian, D. Gross, S. Barnoy, M. Gefen, O. Amran, S. Claerhout, M. Fernández-Vaquero, M. García-Beccaria, D. Heide, M. Shoshkes-Carmel, D. Schmidt Arras, S. Elgavish, Y. Nevo, H. Benyamini, J.E.E. Tirnitz-Parker, A. Sanchez, B. Herrera, R. Safadi, K.H. Kaestner, S. Rose-John, T. Roskams, M. Heikenwalder and E. Galun 1631

REVIEWS

Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease

E.K. Mitten and G. Baffy 1642

Immunobiology of the biliary tract system

N.K. Björkström 1657

SEMINAR

Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion

G.V. Papatheodoridis, V. Lekakis, T. Voulgaris, P. Lampertico, T. Berg, H.L.Y. Chan, J.-H. Kao, N. Terrault, A.S. Lok and K.R. Reddy 1670

SPECIAL SECTIONS

Thematic Miniseries on Cholangiocarcinoma

Current epidemiology of cholangiocarcinoma in Western countries

M. Vithayathil and S.A. Khan 1690

Public Health Corner

Applying an equity lens to liver health and research in Europe

M. Ventura-Cots, R. Bataller, J.V. Lazarus, J. Benach and J.M. Pericàs 1699

Hepatology Snapshot

Hepatopathology of flaviviruses

A.L. Bailey and M.S. Diamond 1711

LETTERS TO THE EDITOR

Peripheral blood CD177⁺ cells as an early diagnostic marker for biliary atresia: A prospective multicentre study in pediatric patients with cholestasis

R. Zhang, J. Huang, J. Shan, Y. Chen and H. Xia 1714

New terms for fatty liver disease other than MAFLD: Time for a reality check

N. Méndez-Sánchez and S.C. Pal 1716

MAFLD 2022: An ELPA/ALPA/EASO-ECPO joint statement on disease stigma

G. Shiha, M. Korenjak, T. Casanovas, V. Mooney, S. Sigurðardóttir, Y. Koulla and R. Soliman 1717

External validation of a genetic risk score that predicts development of alcohol-related cirrhosis

S. Johansen, M. Thiele, H.B. Juel, T. Hansen and A. Krug 1720

Reply to: "External validation of a genetic risk score that predicts development of alcohol-related cirrhosis"

J.B. Whitfield, T.R. Morgan and D. Seth 1721

A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations

Y. Tang, Y. Chen and H.-N. Chen 1722

Reply to: "A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations"

H. Yang, S.H. Bae and J.W. Jang 1724

Challenges and issues in bivariate endpoints in study designs of translational medicine

Q. Zhou 1726

Reply to: "Challenges and issues in bivariate endpoints in study designs of translational medicine"

S. Chuah, D. Tai and V. Chew 1727

An individualized cirrhosis screening strategy might be more cost-effective in the general population

S. Zhao, X. Liao and R. Fan 1728

Reply to: "An individualized cirrhosis screening strategy might be more cost-effective in the general population"

C. Labenz, A. Arslanow, F. Lammert and P.R. Galle 1730

Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]

S. Maimone, V.F. Tripodi and A.T. Mazzeo 1731

Reply to: "Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]"

R. Maiwall, A. Deshmukh and S.K. Sarin 1732

Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.

Cover image: This month's cover features the article "Global burden of primary liver cancer in 2020 and predictions for 2040" by Harriet Rungay et al. on pp. 1598-1606. The cover displays a person struggling, like Sisyphus, to roll an immense boulder up a hill. The liver-shaped boulder is also a map of the globe where continents represent tumour-like stains, it symbolizes the predicted burden of primary liver cancer that humanity will have to bear in the next 20 years. Artwork by Pablo Echeverria.